Cambridge Investment Research Advisors’s Altimmune ALT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34K	Hold	11,206	–	–	﹤0.01%	3731
2026 Q1	$35K	Buy	+11,206	New	+$47.6K	﹤0.01%	3874
2025 Q4	–	Sell	-12,532	Closed	-$47K	–	3816
2025 Q3	$47K	Sell	12,532 -6,136	-33%	-$23.7K	﹤0.01%	3662
2025 Q2	$72K	Buy	18,668 +3,000	+19%	+$16.2K	﹤0.01%	3508
2025 Q1	$78K	Buy	15,668 +1,147	+8%	+$7.27K	﹤0.01%	3378
2024 Q4	$105K	Buy	14,521 +2,400	+20%	+$18.3K	﹤0.01%	3320
2024 Q3	$74K	Buy	+12,121	New	+$82.1K	﹤0.01%	3298

Other funds holding ALT

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BWCS

Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return

BWM

Brown Wealth Management Naperville, Illinois $447M AUM 16.94% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

SFWA

Summit Financial Wealth Advisors Lafayette, Louisiana $782M AUM 24.35% 1-Year Est. Return

KWA

Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Cambridge Investment Research Advisors's ALT Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its Altimmune (ALT) position steady in Q2 2026 at 11,206 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #3731.

Cambridge Investment Research Advisors first reported a position in ALT in Q3 2024 and has held it in 7 quarters since. The position peaked at $105K in Q4 2024. 38 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

Cambridge Investment Research Advisors held 11,206 shares of Altimmune worth $34K as of Q2 2026.
Cambridge Investment Research Advisors left its Altimmune share count unchanged in Q2 2026.
Altimmune made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3731 holding.
Cambridge Investment Research Advisors first reported a position in Altimmune in Q3 2024 and has held it in 7 quarters since.
Cambridge Investment Research Advisors's Altimmune position peaked at $105K in Q4 2024.
38 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.